Patent application number | Description | Published |
20090118203 | Administration of agents inducing dopachrome tautomerase (TRP-2) expression for protecting hair follicle melanocytes - Agents inducing the expression of DOPAchrome tautomerase are administered, notably topically applied, to protect and/or regenerate the melanocytes of hair follicles, to promote the cyclic renewal of the follicular pigmentation unit, to prevent and/or limit and/or arrest the development of canities, and to maintain the natural pigmentation of gray or white head hair and/or body hair. | 05-07-2009 |
20100074929 | ADMINISTRATION OF AGENTS MIMICKING DOPACHROME TAUTOMERASE (TRP-2) ACTIVITY FOR PROTECTING HAIR FOLLICLE MELANOCYTES - Agents mimicking DOPAchrome tautomerase activity are administered, notably topically applied, to protect and/or regenerate the melanocytes of hair follicles, to promote the cyclic renewal of the follicular pigmentation unit, to prevent and/or limit and/or arrest the development of canities, and to maintain the natural pigmentation of gray or white head hair and/or body hair. | 03-25-2010 |
20110014250 | INHIBITORS OF 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE FOR STIMULATING PIGMENTATION OF THE SKIN OR SKIN APPENDAGES - Inhibitors of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), for example tetrazole, styrylpyrazole, phenylfuran, phenylthiophene, phenylpyrrazole, pyrazolecarboxamide, 2-thioacetamide and azo compounds, are useful for promoting or stimulating pigmentation of the skin and/or skin appendages and/or for preventing and/or for limiting depigmentation and/or whitening of the skin and/or skin appendages, notably for preventing and/or limiting canities. | 01-20-2011 |
Patent application number | Description | Published |
20090275033 | Uses of BNIPXL-Beta in premature canities - The present invention concerns the use of a polypeptide comprising a sequence having at least 90% identity with all or part of BNIPXLβ, for cosmetic or therapeutic applications, in the treatment or prevention of premature canities in humans, said portion comprising at least 30 amino acids, as well as the use, for the same purpose, of a molecule comprising a RNAi sequence having at least 90% identity with all or part of the cDNA sequence of BNIPXLβ, said part comprising at least 18 nucleotides. | 11-05-2009 |
20120263812 | USE OF AN EXTRACT OF PUNICA GRANATUM FOR COMBATING CANITIES - The invention relates to the use of at least one plant of the species | 10-18-2012 |
20130149360 | ADMINISTRATION OF COUMARIN, BUTYLATED HYDROXYANISOLE AND ETHOXYQUINE FOR THE TREATMENT OF CANITIES - At least one compound selected from among coumarin and/or derivative thereof, butylated hydroxyanisole, ethoxyquine and mixtures thereof, and admixtures thereof with other active agents selected from among active agents for combating desquamative conditions of the scalp, plant extracts having propigmenting activity and active agents that slow hair loss and/or promote hair regrowth, are useful for preventing and/or limiting and/or stopping the development of canities. | 06-13-2013 |